Journal article

Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib

Justin F Gainor, Daniel SW Tan, Tomasso De Pas, Benjamin J Solomon, Aziah Ahmad, Chiara Lazzari, Filippo de Marinis, Gianluca Spitaleri, Katherine Schultz, Luc Friboulet, Beow Y Yeap, Jeffrey A Engelman, Alice T Shaw

CLINICAL CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2015

Abstract

PURPOSE: Anaplastic lymphoma kinase (ALK) rearrangements are important therapeutic targets in non-small cell lung cancer (NSCLC) that confer sensitivity to the ALK inhibitors crizotinib and ceritinib. To determine the outcome of sequential treatment with crizotinb and ceritinib, we retrospectively evaluated a cohort of ALK-positive patients treated with both agents. EXPERIMENTAL DESIGN: We identified 73 ALK-positive NSCLC patients treated with crizotinib followed by ceritinib at four institutions. Medical records were reviewed to determine overall survival (OS) and progression-free survival (PFS) on crizotinib and ceritinib. RESULTS: Among 73 ALK-positive patients, the median PFS (mPFS) on c..

View full abstract